Antimalarial effects of sulphormethoxine, diaphenylsulphone and separate combinations of these with pyrimethamine: a review of preliminary investigations carried out in Tanzania.
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000302:isolation & purification; D010965:Plasmodium malariae / Q000302:isolation & purification; D010966:Plasmodium vivax / Q000302:isolation & purification; D002727:Proguanil / Q000008:administration & dosage; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013636:Tanzania
D000962:Antimalarials; D013449:Sulfonamides; D002738:Chloroquine; D003622:Dapsone; D002727:Proguanil; D011739:Pyrimethamine